Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer

Yuh Min Chen, Ming Fang Wu, Reury Perng Perng, Chi Ming Chou, Kuang Young Yang, Wei Chun Lin, Chun Ming Tsai, Jacqueline Ming Liu, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity. Between January 1994 and December 1995, 16 patients were treated. Ifosfamide and etoposide doses were ifosfamide 2 g/m2, with mesna, i.v. infusion over 30 minutes on days 1-3 and etoposide 80 mg/m2 i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles. All patients were evaluable for toxicity profile and treatment response. As expected, the major toxicity was myelosuppression. With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia. Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia. One toxic death due to febrile neutropenia with sepsis was documented. Toxicities other than leukopenia were few and mild in severity. After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study. The median duration of response was 8 months and median survival was 11 months. In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.

Original languageEnglish
Pages (from-to)76-79
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume27
Issue number2
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

Fingerprint

Ifosfamide
Small Cell Lung Carcinoma
Etoposide
Drug Therapy
Leukopenia
Febrile Neutropenia
Mesna
Poisons
Sepsis
Therapeutics
Confidence Intervals
Survival

Keywords

  • Etoposide
  • Ifosfamide
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer. / Chen, Yuh Min; Wu, Ming Fang; Perng, Reury Perng; Chou, Chi Ming; Yang, Kuang Young; Lin, Wei Chun; Tsai, Chun Ming; Liu, Jacqueline Ming; Whang-Peng, Jacqueline.

In: Japanese Journal of Clinical Oncology, Vol. 27, No. 2, 01.01.1997, p. 76-79.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Wu, Ming Fang ; Perng, Reury Perng ; Chou, Chi Ming ; Yang, Kuang Young ; Lin, Wei Chun ; Tsai, Chun Ming ; Liu, Jacqueline Ming ; Whang-Peng, Jacqueline. / Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer. In: Japanese Journal of Clinical Oncology. 1997 ; Vol. 27, No. 2. pp. 76-79.
@article{a001696b12be4278a6a3fbfc2593cd99,
title = "Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer",
abstract = "We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity. Between January 1994 and December 1995, 16 patients were treated. Ifosfamide and etoposide doses were ifosfamide 2 g/m2, with mesna, i.v. infusion over 30 minutes on days 1-3 and etoposide 80 mg/m2 i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles. All patients were evaluable for toxicity profile and treatment response. As expected, the major toxicity was myelosuppression. With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7{\%} of the total courses had grade 3 or 4 leukopenia. Nine of 16 patients (56.3{\%}) experienced episodes of febrile neutropenia. One toxic death due to febrile neutropenia with sepsis was documented. Toxicities other than leukopenia were few and mild in severity. After two cycles of treatment, the overall response rate was 81.3{\%} (95{\%} confidence interval 62.2-100) in this study. The median duration of response was 8 months and median survival was 11 months. In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.",
keywords = "Etoposide, Ifosfamide, Small-cell lung cancer",
author = "Chen, {Yuh Min} and Wu, {Ming Fang} and Perng, {Reury Perng} and Chou, {Chi Ming} and Yang, {Kuang Young} and Lin, {Wei Chun} and Tsai, {Chun Ming} and Liu, {Jacqueline Ming} and Jacqueline Whang-Peng",
year = "1997",
month = "1",
day = "1",
doi = "10.1093/jjco/27.2.76",
language = "English",
volume = "27",
pages = "76--79",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer

AU - Chen, Yuh Min

AU - Wu, Ming Fang

AU - Perng, Reury Perng

AU - Chou, Chi Ming

AU - Yang, Kuang Young

AU - Lin, Wei Chun

AU - Tsai, Chun Ming

AU - Liu, Jacqueline Ming

AU - Whang-Peng, Jacqueline

PY - 1997/1/1

Y1 - 1997/1/1

N2 - We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity. Between January 1994 and December 1995, 16 patients were treated. Ifosfamide and etoposide doses were ifosfamide 2 g/m2, with mesna, i.v. infusion over 30 minutes on days 1-3 and etoposide 80 mg/m2 i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles. All patients were evaluable for toxicity profile and treatment response. As expected, the major toxicity was myelosuppression. With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia. Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia. One toxic death due to febrile neutropenia with sepsis was documented. Toxicities other than leukopenia were few and mild in severity. After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study. The median duration of response was 8 months and median survival was 11 months. In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.

AB - We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity. Between January 1994 and December 1995, 16 patients were treated. Ifosfamide and etoposide doses were ifosfamide 2 g/m2, with mesna, i.v. infusion over 30 minutes on days 1-3 and etoposide 80 mg/m2 i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles. All patients were evaluable for toxicity profile and treatment response. As expected, the major toxicity was myelosuppression. With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia. Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia. One toxic death due to febrile neutropenia with sepsis was documented. Toxicities other than leukopenia were few and mild in severity. After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study. The median duration of response was 8 months and median survival was 11 months. In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.

KW - Etoposide

KW - Ifosfamide

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0031110127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031110127&partnerID=8YFLogxK

U2 - 10.1093/jjco/27.2.76

DO - 10.1093/jjco/27.2.76

M3 - Article

VL - 27

SP - 76

EP - 79

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -